Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Comparison Of Respiratory Support After Delivery on Infants Born Before 28 Weeks Gestational Age (CORSAD)

28 mei 2020 bijgewerkt door: Baldvin Jonsson

A Randomised Controlled Trial of Delivery Room Intubation Rates Comparing a New System and T-piece Resuscitation System for Initial Stabilisation of Infants Born <28 Weeks

Trial purpose: For infants born <28 weeks of age, can initial respiratory resuscitation with new system (low imposed work of breathing and prongs) reduce the frequency of delivery room intubations compared to standard treatment with T-piece resuscitator system (high imposed work of breathing and face mask)?

Trial summary: This is a randomised controlled trial of delivery room intubation rates comparing a new system and T-piece resuscitation system for initial stabilisation of infants born <28 weeks.

Studie Overzicht

Gedetailleerde beschrijving

The study is a two arm randomised comparison of two systems (T-piece device and the new system) for respiratory support after delivery of an infant born less than 28 weeks gestational age (GA). This multicentre trial will start at Karolinska University Hospital and other sites can join throughout the study period. The trial is academic with the coordinating investigator as sponsor. No company funding will be considered.

The new device has been designed for neonatal resuscitation and CE-marked for this intended use. The device is operated/handled in a similar way to existing devices and can provide support according to resuscitation guidelines.

During spontaneous breathing the continuous positive airway pressure (CPAP) provided with the new system is more pressure stable and has low imposed work of breathing. The benefits of decreased imposed work of breathing during resuscitation have not previously been investigated. The new system has the option of using prongs as the patient interface. Prongs have shown promising results in trials and have theoretical benefits. We hypothesis that the combined use of prongs and low imposed work of breathing could reduce the number of infants that need mechanical ventilation.

Screening for eligibility and consent will be performed on mothers with threatening delivery of an extremely premature infant (<28 weeks gestational age). There is no lower gestational age limit but patients should not be included if there is a decision to intubate prior to delivery or treatment limitations.

After a patient has been enrolled the randomisation will be on hold until delivery is imminent. Randomisation will be stratified on centre, gestational age and antenatal steroid treatment. The interventions cannot be blinded.

The management of respiratory support is according to international guidelines and a detailed description is provided in the clinical management appendix. The intervention is respiratory support for the first 10-30 minutes of life and will begin after birth when the infant is transferred to the resuscitation team. The intervention ends 1) when an infant is intubated (primary outcome), 2) after a minimum of 10 minutes support, with the randomized system, the patient is stable and breathing adequately, 3) at 30 minutes when the respiratory support can continue as decided by the clinicians (cross-over not allowed).

Apart from the system used for respiratory support all patients will receive standard care. No assessments or investigations of the trial subjects are planned. Data will be reported by the resuscitation team and collected from records.

The primary outcome is delivery room intubation or death. The secondary outcomes include time to intubation, use of surfactant, use of positive pressure ventilation, respiratory support at 72 hours and temperature on intensive care admission. Safety variables include pneumothorax, intraventricular haemorrhage and problems with ventilation and equipment.

All analysis will be on intention to treat and p<0.05 considered statistically significant. The primary outcome variable (delivery room intubation or death) will represent a 2x2 cross table and analysed with Pearson chi-square test. The secondary outcomes include Kaplan Meier analysis of time to intubation and comparisons of means for continuous variables. There are no predetermined subgroups. Subgroup analysis will be used to describe the population and to generate hypotheses.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

250

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Reykjavík, IJsland, 101
        • Department of neonatology, University Hospital of Iceland
      • Vilnius, Litouwen, LT-08406
        • Neonatal Unit, Vilnius University Hospital Santaros Klinikos
      • Stavanger, Noorwegen, 4011
        • Stavanger University Hospital, Department of Pediatrics
      • Poznan, Polen, 60-535
        • Department of Neonatology, Poznan University of Medical Sciences
      • Linköping, Zweden, 58185
        • University Hospital Linköping, Department of Pediatrics
      • Stockholm, Zweden, 171 76
        • Karolinska University Hospital, Neonatology department

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Born <28 weeks gestational age at a university hospital
  2. Delivery can be vaginal or with caesarean section and steroid prophylaxis to mother can be complete, incomplete or not given

Exclusion Criteria:

  1. Decision on treatment limitations before randomisation
  2. Decision to intubate infant made before delivery (for example local routine for infants born before 23 weeks GA)
  3. Known airway, pulmonary, cardiac, gastro-intestinal tract malformations
  4. Known neuromuscular disease
  5. No study neonatologist available

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Reference Device: T-piece System
Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
Andere namen:
  • Neopuff™ Infant T-Piece Resuscitator
  • T-piece Disposable Circuit Kit (GE Healthcare)
  • Other T-piece manufacturers
Actieve vergelijker: Investigational Device: The New System
Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
Andere namen:
  • Manufacturing and CE-marking by Inspiration Healthcare, UK

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Delivery room intubation or death
Tijdsspanne: 0-30 minutes
The primary outcome is delivery room intubation or death. Death has to be included in the primary outcome since patients that die may not always be intubated. The variable is a dichotomous outcome and reported by the resuscitation team.
0-30 minutes

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Time to primary outcome (intubation or death)
Tijdsspanne: up to 72 hours of age
The time (minutes:hours) that a patient reach primary outcome. Data reported by resuscitation team or collected at patient record review of the first three days of life. This is a safety endpoint.
up to 72 hours of age
Death
Tijdsspanne: up to 72 hours of age
The time (minutes:hours) that a patient died. Data reported by resuscitation team or collected at patient record review of the first three days of life. This is a safety endpoint.
up to 72 hours of age
Intra ventricular haemorrhage grade III or more
Tijdsspanne: up to 72 hours of age
The number of patients with an intra ventricular hemorrhage grade III or more. Data collected at patient record review of the first three days of life. This is a safety endpoint.
up to 72 hours of age
Airleaks and pneumothorax
Tijdsspanne: up to 72 hours of age
The number of patients with airleaks or pneumothorax during resuscitation or the first 72 hours of life. Data reported by resuscitation team or collected at patient record review of the first three days of life. This is a safety endpoint.
up to 72 hours of age
Failed ventilation
Tijdsspanne: 0-30 minutes
The number of patients with failed ventilation during resuscitation. Data reported by resuscitation team. This is a safety endpoint.
0-30 minutes
Device problems or malfunction
Tijdsspanne: 0-30 minutes
The instances that there was a problem with the randomized intervention. Data reported by resuscitation team. This is a safety endpoint. Device problems or malfunction activates the adverse events handling protocol.
0-30 minutes

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Surfactant use in delivery room (DR) and neonatal intensive care unit (NICU)
Tijdsspanne: up to 72 hours of age
The number of patients, method used and the number of doses that a patient received in the DR and NICU. Data reported by resuscitation team or collected at patient record review of the first three days of life.
up to 72 hours of age
The use of positive pressure ventilation (PPV) in delivery room
Tijdsspanne: 0-30 minutes
The number of patients that needed PPV during resuscitation. Data reported by resuscitation team.
0-30 minutes
Use of sustained inflation (not recommended)
Tijdsspanne: 0-30 minutes
The number of patients that were treated with a sustained inflation during resuscitation. This is not recommended and a violation of protocol. Data reported by resuscitation team.
0-30 minutes
Reason for DR intubation
Tijdsspanne: 0-30 minutes
The main reason for intubating patients in the DR during resuscitation. Data reported by resuscitation team.
0-30 minutes
Response to resuscitation measured by APGAR at 1, 5 and 10 minutes
Tijdsspanne: 1-10 minutes
The initial status of the patient and response to resuscitation measured by APGAR-scores (0-2 points on the five standard criteria). Data reported by resuscitation team.
1-10 minutes
Inspired oxygen level, oxygen saturation (SpO2) and level of CPAP support at 5 and 10 minutes
Tijdsspanne: 5-10 minutes
The initial status of the patient and response to resuscitation measured by need for oxygen (%), SpO2 (%) and the level of CPAP support (cm H2O). Data reported by resuscitation team.
5-10 minutes
Patient temperature on NICU admission
Tijdsspanne: 10-180 minutes
The temperature of the patients when they arrive to NICU (°C). Data collected at patient record review of the first three days of life.
10-180 minutes
Reason for NICU intubation
Tijdsspanne: up to 72 hours of age
The main reason for intubating patients in the NICU. Data collected at patient record review of the first three days of life.
up to 72 hours of age
Mechanical ventilation at any time <72 h
Tijdsspanne: up to 72 hours of age
The number of patients that has received mechanical ventilation at any time <72 hours. Data collected at patient record review of the first three days of life.
up to 72 hours of age
Mechanical ventilation or mode of non-invasive support at 72 h
Tijdsspanne: at 72 hours of age
The number of patients that had mechanical ventilation or non-invasive support at three days of age (including type of support). Data collected at patient record review of the first three days of life.
at 72 hours of age
Decisions on treatment limitations during resuscitation
Tijdsspanne: 0-30 minutes
The number of patients that had any decision on limitations of treatment during resuscitation. Data reported by resuscitation team.
0-30 minutes
Withdrawal or withholding treatment
Tijdsspanne: up to 72 hours of age
The number of patients that had any decision on withdrawal or withholding treatment in the DR or NICU. Data collected at patient record review of the first three days of life.
up to 72 hours of age

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: Baldvin Jonsson, MD, PhD, Karolinska Institutet

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 maart 2016

Primaire voltooiing (Werkelijk)

15 mei 2020

Studie voltooiing (Werkelijk)

18 mei 2020

Studieregistratiedata

Eerst ingediend

24 september 2015

Eerst ingediend dat voldeed aan de QC-criteria

28 september 2015

Eerst geplaatst (Schatting)

30 september 2015

Updates van studierecords

Laatste update geplaatst (Werkelijk)

1 juni 2020

Laatste update ingediend die voldeed aan QC-criteria

28 mei 2020

Laatst geverifieerd

1 mei 2020

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

Onbeslist

Beschrijving IPD-plan

Data will be shared but method of sharing not decided

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren